3(5)-(4-fluorophenyl)-4-(4-pyridyl)pyrazole | 216504-75-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3(5)-(4-fluorophenyl)-4-(4-pyridyl)pyrazole
• 英文别名: 5-(4-Fluorophenyl)-4-(pyridin-4-yl)pyrazole；4-[3-(4-Fluorophenyl)-1h-Pyrazol-4-Yl]pyridine；4-[5-(4-fluorophenyl)-1H-pyrazol-4-yl]pyridine
• CAS: 216504-75-5
• 化学式: C₁₄H₁₀FN₃
• 分子量: 239.252
• InChiKey: BILJSHVAAVZERY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3(5)-(4-fluorophenyl)-4-(4-pyridyl)pyrazole 在 正丁基锂 作用下， 以 四氢呋喃 、 乙醇 、 正己烷 为溶剂， 反应 6.67h， 生成 3-(4-fluorophenyl)-5-(1-hydroxy-3-phenylpropyl)-4-(4-pyridyl)pyrazole
  参考文献：
  名称：

  Design and synthesis of 5-[(2-chloro-6-fluorophenyl)acetylamino]-3-(4-fluorophenyl)-4-(4-pyrimidinyl)isoxazole (AKP-001), a novel inhibitor of p38 MAP kinase with reduced side effects based on the antedrug concept

  摘要：

  Inhibitors of p38 mitogen-activated protein (MAP) kinase, which are closely involved in the production of inflammatory cytokines, are considered promising curative drugs for chronic inflammatory disorders. However, there is also a growing concern regarding its systemic side effects. To reduce the occurrence of side effects, we have identified a novel p38 MAP kinase inhibitor that shows properties of an antedrug, which imparts its effect solely on the inflammatory site and is metabolically inactivated right after. We have designed isoxazole derivatives through the addition of a fresh interacting fourth site to the structure of the prototypical p38 MAP kinase inhibitor that harbors three point interactive sites. The derivative 26d (AKP-001) shows excellent p38 MAP kinase inhibitory activity and a high selectivity for various kinases. Its rapid metabolism has been confirmed in rats. Moreover, 26d has been shown to be effective in animal models of inflammatory bowel disease.

  DOI：

  10.1016/j.bmc.2014.05.045
• 作为产物：
  描述：

  3-dimethylamino-1-(4-fluorophenyl)-2-(4-pyridyl)-2-propen-1-one 在 肼 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以86%的产率得到3(5)-(4-fluorophenyl)-4-(4-pyridyl)pyrazole
  参考文献：
  名称：

  Substituted pyrazole compounds

  摘要：

  本发明公开了由式(I)表示的取代吡唑化合物或其盐，其中R1为—CH(OH)—CH(R4)—(A)n—Y，—CH2—CH(R4)—(A)n—Y，—CO—B1—A—Y或类似物（其中A为较低的烷基；Y为芳基，可以被卤素等取代；R4为氢原子或较低烷基基团；B1为—CH(R4)—或—N(R4)—；n为0或1）；R2为氢原子，可以被羟基等取代的较低烷基基团，或芳基烷基基团；R3为可以被卤素等取代的苯基或吡啶基；Q为吡啶基或喹啉基。这些取代的吡唑化合物或其盐具有优异的p38MAP激酶抑制作用，因此在预防或治疗肿瘤坏死因子α相关疾病、白细胞介素1相关疾病、白细胞介素6相关疾病或环氧合酶II相关疾病方面非常有用。

  公开号：

  US06667325B1
• 作为试剂：
  描述：

  4-[1-(tetrahydro-2H-pyran-2-yl)-5-(tributylstannyl)-1H-pyrazol-4-yl]pyridine 、 对溴氟苯 、 氟化铯 在 四(三苯基膦)钯 、 碘化亚铜 crude mixture 、 crude product 、 silica gel 、 cyclohexane, ethyl acetate 、 4-[5-(4-fluorophenyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl]pyridine 、 cleaved product 、 3(5)-(4-fluorophenyl)-4-(4-pyridyl)pyrazole 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 0.42h， 生成 4-[5-(4-fluorophenyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl]pyridine
  参考文献：
  名称：

  Phenylpyri(mi)dinylazoles

  摘要：

  公式[I-a]和[I-b]的苯基吡啶基氮唑，其中符号的含义在描述中说明，以及其农药活性盐以及用于控制保护植物和材料中的不良微生物和减少植物和植物部分中霉菌毒素的用途，以及公式[I-a]和[I-b]化合物的生产方法。

  公开号：

  US20130281455A1

文献信息

• CYCLIC TERTIARY AMINE COMPOUND
  申请人：Sankyo Company, Limited

  公开号：EP1632488A1

  公开（公告）日：2006-03-08

  The present invention provides a cyclic tertiary amine compound which is capable of inhibiting the production of inflammatory cytokines. It is either a compound having a structure represented by the following general formula (I): (wherein A represents an optionally substituted trivalent group derived from pyrimidine, pyrrole, or the like; R1 represents an aryl or a heteroaryl group which may optionally be substituted; R2 represents a heteroaryl group which may optionally be substituted; and R3 represents a cyclic tertiary amino group) or a pharmacologically acceptable salt of the compound.

  本发明提供了一种能够抑制炎症细胞因子产生的环状三级胺化合物。它是具有以下一般式(I)所表示结构的化合物：（其中A表示从嘧啶、吡咯等衍生的可选择取代的三价基团；R1表示可能被取代的芳基或杂环芳基团；R2表示可能被取代的杂环芳基团；R3表示环状三级胺基团），或该化合物的药理学可接受的盐。
• [EN] SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS<br/>[FR] PYRAZOLES SUBSTITUES UTILISES COMME INHIBITEURS DE LA KINASE p38
  申请人：SEARLE & CO

  公开号：WO2000031063A1

  公开（公告）日：2000-06-02

  A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula (IA), wherein R?1, R2, R3 and R4¿ are as described in the specification.

  本文描述了一类吡唑衍生物，用于治疗p38激酶介导的疾病。 特别感兴趣的化合物由公式（IA）定义，其中R?1，R2，R3和R4¿如规范中所述。
• Bicyclic unsaturated tertiary amine compounds
  申请人：Kimura Tomio

  公开号：US20050159444A1

  公开（公告）日：2005-07-21

  A bicyclic unsaturated tertiary amine compound capable of inhibiting the production of inflammatory cytokines. The compound has the following formula (I): wherein A represents pyrrole or pyrazole, R 1 represents an aryl group or a heteroaryl group which may be substituted, R 2 represents a heteroaryl group which may be substituted, and R 3 represents an indolizine group, or a pharmacologically acceptable salt thereof, a pharmacologically acceptable ester thereof or a pharmacologically acceptable derivative thereof.

  一种双环不饱和三级胺化合物，能够抑制炎症细胞因子的产生。该化合物的化学式如下（I）：其中A代表吡咯或吡唑，R1代表取代的芳基或杂环基，R2代表取代的杂环基，R3代表吲哚啉基，或其药学上可接受的盐、酯或衍生物。
• Compounds substituted with bicyclic amino groups
  申请人：SANKYO COMPANY, LIMITED

  公开号：US20040147525A1

  公开（公告）日：2004-07-29

  Compounds of the formula (I) below, or pharmacologically acceptable salts, esters or other derivatives thereof: 1 wherein A is furan, thiophene, pyrazole, imidazole, isoxazole or isothiazole; R 1 is a substituted or unsubstituted aryl or a substituted or unsubstituted heteroaryl; R 2 is a substituted or unsubstituted heteroaryl; and R 3 is a bicyclic amino group; provided that the substituents R 1 and R 2 are bonded to the two atoms of the cyclic group A which are adjacent to the atom of the cyclic group A to which the substituent R 2 is bonded. The compounds inhibit the production of inflammatory cytokines.

  以下式子（I）的化合物，或其药理学上可接受的盐，酯或其他衍生物：1其中A是呋喃，噻吩，吡唑，咪唑，异唑或异噻唑; R1是取代或未取代的芳基或取代或未取代的杂环芳基; R2是取代或未取代的杂环芳基; R3是双环氨基; 前提是取代基R1和R2与环族A的两个原子相连，这些原子邻接于取代基R2所连接的环族A原子。这些化合物抑制炎性细胞因子的产生。
• Pyrazole compounds
  申请人：Hagihara Masahiko

  公开号：US20060063934A1

  公开（公告）日：2006-03-23

  The present invention relates to pyrazole compounds represented by the formula (I): wherein R 1 represents phenyl which may be substituted, R 2 represents H, halogen, alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl or substituted amino, Q represents CH or N, R 3 represents H, alkyl or amino, R 4 represents the formula (II) to (V): wherein R 7 represents H or alkyl, R 8 represents H, alkyl or substituted amino, R 9 represents H or alkyl, R 12 represents H, alkyl, halogeno alkyl or substituted amino, or pharmaceutically acceptable salts thereof, and a medical composition containing the same as effective ingredient.

  本发明涉及由式（I）表示的吡唑化合物，其中R1表示可能被取代的苯基，R2表示H、卤素、烷基、烷氧基、烷硫基、烷基亚砜基、烷基磺酰基或取代的氨基，Q表示CH或N，R3表示H、烷基或氨基，R4表示式（II）至（V）：其中R7表示H或烷基，R8表示H、烷基或取代的氨基，R9表示H或烷基，R12表示H、烷基、卤代烷基或取代的氨基，或其药学上可接受的盐，以及含有其作为有效成分的医药组合物。